AN2 Therapeutics, Inc. Common Stock

ANTX US0373261058

💰
Capitalization
Small-cap

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

🔗
Website
https://www.an2therapeutics.com
Annual Performance 1
2022 2023 2024 2025
-38% 111% -93% 2%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
48
🙍
Insiders
11
Person Price Shares Total Published Completed
Easom Eric
CEO 		1.07
USD 		10,000
Bought 		10,665
USD 		02/06/2025 02/06/2025
Leonard Braden Michael
 1.03
USD 		7,000
Sold 		7,227
USD 		28/05/2025 30/05/2025
Leonard Braden Michael
 1.01
USD 		425,000
Sold 		429,250
USD 		28/05/2025 30/05/2025
Leonard Braden Michael
 1.03
USD 		7,000
Sold 		7,227
USD 		28/05/2025 30/05/2025
Leonard Braden Michael
 1.01
USD 		425,000
Sold 		429,250
USD 		28/05/2025 30/05/2025
Fitzpatrick Margaret M
 1.18
USD 		8,610
Bought 		10,133
USD 		28/05/2025 28/05/2025
Leonard Braden Michael
 1.16
USD 		2,000,000
Sold 		2,320,000
USD 		28/05/2025 28/05/2025
Leonard Braden Michael
 1.09
USD 		200,000
Sold 		218,000
USD 		12/06/2025 28/05/2025
Fitzpatrick Margaret M
 1.18
USD 		8,610
Bought 		10,133
USD 		28/05/2025 28/05/2025
Leonard Braden Michael
 1.16
USD 		100,000
Sold 		116,000
USD 		28/05/2025 28/05/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include AN2 Therapeutics, Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
38% -46% -53% -80% 0% 0% -91%
Last 52W Low 52W High All-Time Low All-Time High β
1.31 1.00 1.67 0.98 22.29
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Leonard Braden Michael 11 7,740,953.60 703,723.05 14/08/2024 30/05/2025
Aziz Kabeer 4 1,994,224.26 498,556.07 14/11/2023 16/01/2024
Zakrzewski Joseph S 4 1,939,256.00 484,814.00 18/01/2024 27/11/2024
Readnour Robin Shane 18 517,192.49 28,732.92 10/01/2024 10/12/2024
Krause Kevin Michael 2 201,334.37 100,667.18 02/01/2024 09/01/2024
Easom Eric 3 116,437.43 38,812.48 02/01/2024 02/06/2025
Fitzpatrick Margaret M 2 20,266.22 10,133.11 28/05/2025 28/05/2025
Eizen Joshua M 1 12,958.08 12,958.08 03/01/2025 03/01/2025
Chanda Sanjay 1 3,965.34 3,965.34 03/01/2025 03/01/2025
Day Lucy 1 3,965.34 3,965.34 03/01/2025 03/01/2025
Prior Stephen David 1 2,720.89 2,720.89 03/01/2025 03/01/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.